IO Biotech Inc

NASDAQ IOBT

Data sourced from

and

Download Data

IO Biotech Inc Net Income for the year ending December 31, 2023: USD -86.08 M

IO Biotech Inc Net Income is USD -86.08 M for the year ending December 31, 2023, a -20.47% change year over year. Net Income is the profit earned by a company after deducting all expenses, including taxes and non-controlling interest.

IO Biotech Inc Net Income for the year ending December 31, 2022 was USD -71.46 M, a -5.27% change year over year.
IO Biotech Inc Net Income for the year ending December 31, 2021 was USD -67.88 M, a -463.69% change year over year.
IO Biotech Inc Net Income for the year ending December 31, 2020 was USD -12.04 M, a -12.09% change year over year.
IO Biotech Inc Net Income for the year ending December 31, 2019 was USD -10.74 M.

NASDAQ: IOBT

IO Biotech Inc

CEO	Dr. Mai-Britt Zocca Ph.D.
IPO Date	Nov. 5, 2021
Location	Denmark
Headquarters	Ole Maaløes Vej 3, Copenhagen, Denmark, 2200
Employees	68
Sector	Healthcare
Industry	Biotechnology

Description

IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive mechanisms mediated by Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 2 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.

Key trends